ENST00000485743.1:c.316G>T
Variant summary
Our verdict is Pathogenic. Variant got 26 ACMG points: 26P and 0B. PS1_Very_StrongPM1PM2PM5PP3_StrongPP5_Very_Strong
The ENST00000485743.1(HBB):c.316G>T(p.Val106Leu) variant causes a missense change. The variant allele was found at a frequency of 0.00000657 in 152,150 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another nucleotide change resulting in the same amino acid substitution has been previously reported as Likely pathogenic in ClinVar. Another variant affecting the same amino acid position, but resulting in a different missense (i.e. V106A) has been classified as Pathogenic.
Frequency
Consequence
ENST00000485743.1 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 26 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152150Hom.: 0 Cov.: 32
GnomAD4 exome Cov.: 35
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152150Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74304
ClinVar
Submissions by phenotype
beta Thalassemia Pathogenic:2
- -
Variant summary: HBB c.315+1G>T is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: Four predict the variant abolishes a 5' splicing donor site. However, these predictions have yet to be confirmed by functional studies. The variant was absent in 276896 control chromosomes. c.315+1G>T has been reported in the literature in individuals affected with Beta Thalassemia. These data indicate that the variant is likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as pathogenic. -
not provided Pathogenic:2
The HBB c.315+1G>T variant (also known as IVS-II-1 (G>T)) disrupts a canonical splice-donor site and interferes with normal HBB mRNA splicing. The frequency of this variant in the general population, 0.0000066 (1/152150 chromosomes, http://gnomad.broadinstitute.org), is consistent with pathogenicity. In the published literature, the variant has been reported in individuals with beta-thalassemia (PMID: 3828533 (1987), PMID: 20524821 (2010)). Based on the available information, this variant is classified as pathogenic. Genetic counseling and testing of at-risk relatives are recommended. -
The HBB c.315+1G>T variant (rs33945777), also known as IVS II-1 (G>T), is reported in the literature in individuals affected with beta(0) thalassemia (see HbVar, Broquere 2010, Chehab 1987). This variant is reported in ClinVar (Variation ID: 619686). This variant is absent from the Genome Aggregation Database, indicating it is not a common polymorphism. This variant disrupts the canonical splice donor site of intron 2, which is likely to negatively impact gene function. Based on available information, this variant is considered to be pathogenic. References: Link to HbVar database for c.315+1G>T: http://globin.bx.psu.edu/cgi-bin/hbvar/query_vars3?mode=output&display_format=page&i=2602&.cgifields=histD Broquere C et al. Phenotypic expression and origin of the rare beta-thalassemia splice site mutation HBB:c.315 + 1G>T. Hemoglobin. 2010 Jun;34(3):322-6. Chehab FF et al. The molecular basis of beta-thalassemia in Lebanon: application to prenatal diagnosis. Blood. 1987 Apr;69(4):1141-5. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at